Search results
Street calls of the week: Upgrade for Shopify; downgrades for AMD, Paramount
Investing.com via Yahoo Finance· 1 day agoThe company’s two primary assets, setrusumab and alvelestat, originate from large pharmaceutical companies (Novartis/NVS and AstraZeneca/AZN, respectively). In the brokerage ...
This startup helps Americans get Ozempic and Adderall by using overseas freelancers
Quartz· 6 days agoA startup is working to help Americans navigate ongoing shortages of highly-coveted drugs like...
3 Crazy Good Stocks to Buy With $500 Right Now
InvestorPlace· 5 days agoAlthough there was a time when the stock market was solely the playground of the wealthy, it no longer takes money to make money on Wall Street. Revenue...
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It
Motley Fool via Yahoo Finance· 2 days agoRoche recently unveiled encouraging results from a trial involving its GLP-1 drug, CT-338. It helped...
Making Tough Decisions: A Candid Discussion Between Oncs
Medscape· 4 days agoDrs Mark Lewis and Don Dizon discuss what keeps them up at night.
Study finds how lung cancer mutations may influence treatment response
Euronews via Yahoo News· 3 days agoMutations in these proteins are often hallmarks of cancer which is why the team of researchers from...
Surviving to Thriving: Enhancing QoL in Breast Cancer
Medscape· 3 days agoThe growing number of breast cancer survivors highlights the need for holistic and coordinated...
CDC Warns About Chocolate Brand; Raw Garlic and Acne; Odd Appeal of Cow Pedicures
MedPage Today· 4 days agoThe CDC joined the FDA in warning about severe illnesses among consumers of Diamond Shruumz brand...
Pre-diabetes rates increase amidst a renaissance for type 2 diabetes research
Pharmaceutical Technology via Yahoo Finance· 3 days agoNovo Nordisk has a market cap of $436bn while Eli Lilly’s market cap is $839.5bn. Their success has...
A Benefit to Add-On Abemaciclib in Advanced Breast Cancer?
Medscape· 4 days agoAdding abemaciclib to an aromatase inhibitor improved overall survival in HR+/HER2− advanced breast...